Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients

HIV Clinical Trials

Volumn 3, Issue 1, 2002, Pages 36-44

  Clevenbergh, P ^a   Cua, E ^a   Dam, E ^a   Durant, J ^a   Schmit, J C ^a   Boulme, R ^a   Cottalorda, J ^a   Beyou, A ^a   Schapiro, J M ^a   Clavel, F ^a   Dellamonica, P ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Genotypic resistance; NNRTI; Phenotypic susceptibility; Polymorphism

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL;

EID: 0036190937     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/5H0R-UDC8-8RR7-XEMJ     Document Type: Article

References (29)

1. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infected adults. Study 006 Team
2. Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS Study Team
3. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use
4. Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: Pharmacokinetic drug interactions and antiviral activity
5. Initial therapy with protease inhibitor-sparing regimens: Evaluation of nevirapine and delavirdine
6. Protease inhibitor (PI) to nonnucleoside reverse transcriptase inhibitor (NNRTI) switch in an HIV infected inner city cohort
7. Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naive patients (Study DMP 266-006)
8. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
9. HIV-1 drug resistance in newly infected individuals
10. Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: A French nationwide study
11. Natural variation in susceptibility to non-nucleoside reverse transcriptase inhibitors predates drug availability
12. Non-nucleoside reverse transcriptase inhibitor viral hyper-sensitivity is common and improves short-term virological response
13. Efficacy and safety of Buxuxs sempervirens L. preparations (SPV30) in HIV infected asymptomatic patients: A multicenter, randomized, double-blind, placebo-controlled trial
14. Dossier médical informatisé pour les patients attients d'infection par le VIH (ADDIS)
15. Antiretroviral drug resistance testing in HIV infection of adults: Implications for clinical management
16. Phenotypic analysis of the VIRADAPT study: Correlation with genotypic resistance testing and PI plasma levels
17. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan
18. Prevalence of drug resistance mutations among therapy-naive persons newly infected with HIV and pregnant women in two US cities
19. Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors
20. Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy
21. L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase
22. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing
23. Variant human immunodeficiency virus type 1 proteases and response to combination therapy including a protease inhibitor
24. Drug resistance-related mutations in the pol gene of non-subtype B HIV-1 patient strains
25. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: Impact on virological response to efavirenz-based therapy
26. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
27. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
28. Persisting longterm benefit of genotype-guided treatment for HIV-infected patients failing HAART. The VIRADAPT study: Week 48 follow-up
29. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy